Zhou Ming, Ge Xiaoxu, Xu Xiaoming, Sheng Biao, Wang Hao, Shi Haoyu, Liu Sikun, Tan Boren, Xu Kailun, Wang Jian
Department of Colorectal Surgery and Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, P.R. China.
Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, Hangzhou, Zhejiang 310000, P.R. China.
Oncol Lett. 2024 Jul 3;28(3):419. doi: 10.3892/ol.2024.14552. eCollection 2024 Sep.
Globally, colorectal cancer (CRC) is one of the most lethal and prevalent malignancies. Based on the presence of immune cell infiltration in the tumor microenvironment, CRC can be divided into immunologically 'hot' or 'cold' tumors, which in turn leads to the differential efficacy of immunotherapy. However, the immune characteristics of hot and cold CRC tumors remain largely elusive, prompting further investigation of their properties regarding the tumor microenvironment. In the present study, a predictive model was developed based on the differential expression of proteins between cold and hot CRC tumors. First, the differentially expressed proteins (DEPs) were identified using digital spatial profiling and mass spectrometry-based proteomics analysis, and the pathway features of the DEPs were analyzed using functional enrichment analysis. A novel eight-gene signature prognostic risk model was developed ( and ), which was validated using data obtained from The Cancer Genome Atlas. The results revealed that the risk score of the eight-gene signature acted as an independent prognostic indicator in patients with stage II CRC (T3-4N0M0). It was also found that a high-risk score in the eight-gene signature was associated with high immune cell infiltration in patients with CRC. Taken together, these findings revealed some of the differential immune characteristics of hot and cold CRC tumors, and an eight-gene signature prognostic risk model was developed, which may serve as an independent prognostic indicator for patients with stage II CRC (T3-4N0M0).
在全球范围内，结直肠癌（CRC）是最致命且最常见的恶性肿瘤之一。根据肿瘤微环境中免疫细胞浸润的情况，CRC可分为免疫“热”肿瘤或“冷”肿瘤，这进而导致免疫治疗的疗效存在差异。然而，热型和冷型CRC肿瘤的免疫特征在很大程度上仍不清楚，这促使人们进一步研究它们在肿瘤微环境方面的特性。在本研究中，基于冷型和热型CRC肿瘤之间蛋白质的差异表达建立了一个预测模型。首先，使用数字空间分析和基于质谱的蛋白质组学分析来鉴定差异表达蛋白（DEP），并使用功能富集分析来分析DEP的通路特征。开发了一种新的八基因特征预后风险模型（ 以及 ），并使用从癌症基因组图谱获得的数据进行了验证。结果显示，八基因特征的风险评分在II期CRC（T3 - 4N0M0）患者中可作为独立的预后指标。还发现八基因特征中的高风险评分与CRC患者的高免疫细胞浸润相关。综上所述，这些发现揭示了热型和冷型CRC肿瘤的一些差异免疫特征，并建立了一个八基因特征预后风险模型，该模型可作为II期CRC（T3 - 4N0M0）患者的独立预后指标。
